What is the equity of Beigene this year?
Beigene has equity of 25.1 B USD this year.
Beigene Equity 2024
Beigene Equity
25.1 B USD
Ticker
6160.HK
ISIN
KYG1146Y1017
WKN
A144EN
In 2024, Beigene's equity was 25.1 B USD, a -17.24% increase from the 30.33 B USD equity in the previous year.
Beigene Aktienanalyse
What does Beigene do?
Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Beigene's Equity
Beigene's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Beigene's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Beigene's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Beigene's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Beigene’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Beigene stock
What was the equity of Beigene compared to the previous year?
The equity of Beigene has increased/decreased by -17.24% decreased compared to the previous year.
What impact does a high equity have on investors of Beigene?
A high equity is advantageous for investors of Beigene as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Beigene?
A low equity can be a risk for investors of Beigene, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Beigene affect the company?
An increase in equity of Beigene can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Beigene affect the company?
A reduction in equity of Beigene can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Beigene?
Some factors that can affect the equity of Beigene include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Beigene so important for investors?
The equity of Beigene is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Beigene take to change the equity?
To change equity, Beigene can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Beigene pay?
Over the past 12 months, Beigene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Beigene is expected to pay a dividend of 0 USD.
What is the dividend yield of Beigene?
The current dividend yield of Beigene is .
When does Beigene pay dividends?
Beigene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Beigene?
Beigene paid dividends every year for the past 0 years.
What is the dividend of Beigene?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Beigene located?
Beigene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Beigene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Beigene from 9/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/15/2024.
When did Beigene pay the last dividend?
The last dividend was paid out on 9/15/2024.
What was the dividend of Beigene in the year 2023?
In the year 2023, Beigene distributed 0 USD as dividends.
In which currency does Beigene pay out the dividend?
The dividends of Beigene are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Beigene
Our stock analysis for Beigene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beigene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
